Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $5.00 at Barclays
Editas Medicine (NASDAQ:EDIT – Get Free Report) had its target price reduced by investment analysts at Barclays from $7.00 to $5.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s price objective indicates a potential upside of 52.44% from […]
More Stories
Henry Schein (NASDAQ:HSIC) Announces Quarterly Earnings Results
Henry Schein (NASDAQ:HSIC – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $1.22 earnings per...
Apellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results, Misses Estimates By $0.14 EPS
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.46) earnings per...
Insider Selling: Agilysys, Inc. (NASDAQ:AGYS) Director Sells 500 Shares of Stock
Agilysys, Inc. (NASDAQ:AGYS – Get Free Report) Director John Mutch sold 500 shares of the company’s stock in a transaction...
Reviewing Adstar (OTCMKTS:ADST) & Sprinklr (NYSE:CXM)
Sprinklr (NYSE:CXM – Get Free Report) and Adstar (OTCMKTS:ADST – Get Free Report) are both business services companies, but which...
Sow Good (OTCMKTS:SOWG) Stock Price Up 6.9% – Here’s What Happened
Sow Good Inc. (OTCMKTS:SOWG – Get Free Report)’s stock price was up 6.9% on Tuesday . The company traded as...
Thomasville Bancshares (OTCMKTS:THVB) Trading Down 0.2% – Time to Sell?
Thomasville Bancshares, Inc. (OTCMKTS:THVB – Get Free Report)’s share price dropped 0.2% during trading on Tuesday . The stock traded...